Allergan has acquired development and commercialization rights to interstitial cystitis/ bladder pain syndrome therapy LiRIS (lidocaine) from Taris Biomedical.
Allergan has acquired development and commercialization rights to interstitial cystitis/ bladder pain syndrome therapy LiRIS (lidocaine) from Taris Biomedical.
Allergan is paying $67.5m in cash upfront for the product which is currently in Phase II trials. The Irvine, California-based...
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
The Belgian drugmaker is boosting its biologics capacity over the pond.
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.
